EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

CXCL1 in triple‑negative breast cancer: Mechanisms, challenges, and therapeutic opportunities (Review)

Hiba Al Sayegh, Zahraa Assi, Amjad Kanaan, Mirvat El Sibai

Oncology Reports · 2026

DOI: 10.3892/or.2026.9091 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Reports, 2026. Verfasst von Hiba Al Sayegh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Lebanese American University, Beirut 1102‑2801, Lebanon. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Chemokine CXCL1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple negative breast cancer (TNBC) is an aggressive BC subtype with limited therapeutic options and poor clinical outcomes. This subtype accounts for 15‑20% of all BC cases and contributes to nearly 40% of BC mortalities. The chemokine C‑X‑C motif ligand 1 (CXCL1) is a key player in TNBC progression through several signaling pathways, including NF‑κB, MAPK and related cascades. CXCL1 contributes to tumor growth, metastasis, immune modulation and resistance to therapy, however its role and therapeutic potential in TNBC has not been comprehensively described. The present review aimed to summarize CXCL1 biology in TNBC, with a focus on its prognostic relevance, role in the tumor microenvironment and potential as a therapeutic target, as well as emerging strategies aimed at modulating CXCL1 signaling. However, challenges remain in translating these findings into clinical application, including incomplete understanding of certain molecular mechanisms underlying CXCL1 function, unclear prognostic value, the need for validation of potential inhibitors in large and diverse cohorts and the lack of well‑designed clinical trials testing CXCL1‑targeted approaches. Addressing these challenges through rigorous preclinical work and carefully designed clinical trials is key to define the true therapeutic potential of CXCL1 in TNBC to advance precision medicine strategies and enhance clinical outcomes in patients with TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsChemokine CXCL1HumansFemaleTumor MicroenvironmentPrognosisSignal TransductionMolecular Targeted TherapyGene Expression Regulation, NeoplasticBiomarkers, TumorDrug Resistance, Neoplasm

Stichwörter der Autor:innen

CXCL1CXCR2TNBCchemokinechemotherapy resistancemetastasistherapeutic targettumor microenvironment

Substanzen

Chemokine CXCL1CXCL1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biological Sciences, Lebanese American University, Beirut 1102‑2801, Lebanon.
  • Department of Biomedical Sciences, School of Medicine, University of Balamand, Beirut 1100‑2807, Lebanon.

Zitieren

APA

Al Sayegh, H., Assi, Z., Kanaan, A., & El Sibai, M. (2026). CXCL1 in triple‑negative breast cancer: Mechanisms, challenges, and therapeutic opportunities (Review). Oncology Reports. https://doi.org/10.3892/or.2026.9091

Vancouver

Al Sayegh H, Assi Z, Kanaan A, El Sibai M. CXCL1 in triple‑negative breast cancer: Mechanisms, challenges, and therapeutic opportunities (Review). Oncology Reports. 2026. doi:10.3892/or.2026.9091

BibTeX
@article{AlSayegh2026,
  author = {Al Sayegh, Hiba and Assi, Zahraa and Kanaan, Amjad and El Sibai, Mirvat},
  title = {CXCL1 in triple‑negative breast cancer: Mechanisms, challenges, and therapeutic opportunities (Review)},
  journal = {Oncology Reports},
  year = {2026},
  doi = {10.3892/or.2026.9091}
}
Kostenlos starten →